Novartis has announced that the FDA has granted Priority Review status to Scemblix® (asciminib) for treating newly diagnosed adults with Philadelphia chromosome-positive chronic myeloid leukemia

Boehringer Ingelheim has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a new indication for SPEVIGO®

Shanghai Junshi Biosciences Co., Ltd., a prominent biopharmaceutical firm focused on innovation, along with its subsidiary TopAlliance Biosciences Inc., has received a positive opinion from the Committee for Medicinal Products

Checkpoint Therapeutics, Inc., a company specializing in immunotherapy and targeted oncology, has announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted Biologics License Application (BLA) for cosibelimab. This anti-PD-L1 antibody

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company focused on advancing cell therapies for AL Amyloidosis and autoimmune conditions, has received an $8 million CLIN2 grant from the California Institute for Regenerative Medicine

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in novel treatments for rare genetic skin disorders without FDA-approved options, has agreed to merge with Pieris Pharmaceuticals, Inc.

Annovis Bio Inc. has achieved a notable milestone with the issuance of a U.S. patent for its leading drug candidate, buntanetap, which is being investigated for the treatment of acute traumatic brain injuries

Spinogenix, Inc., a biopharmaceutical company at the forefront of developing innovative therapies to restore synaptic function, has announced the start of enrollment for its Phase 2 clinical trial of SPG601. This study aims to assess the drug's

Diamyd Medical has received encouraging feedback from the U.S. Food and Drug Administration concerning an Accelerated Approval pathway for its immunotherapy, Diamyd®, designed for Stage 3 Type 1 Diabetes patients with the HLA DR3-DQ2 genotype.

Johnson & Johnson has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to gain approval for SPRAVATO® (esketamine) CIII nasal spray as a monotherapy for adults with treatment-resistant depression